US 12,337,026 B2
Methods of treating inflammatory disorders with multivalent Fc compounds
David S. Block, Baltimore, MD (US); and Henrik Olsen, Baltimore, MD (US)
Assigned to Gliknik Inc., Baltimore, MD (US)
Filed by Gliknik Inc., Baltimore, MD (US)
Filed on Apr. 12, 2022, as Appl. No. 17/718,822.
Application 17/718,822 is a division of application No. 16/467,859, granted, now 11,331,372, previously published as PCT/US2017/065400, filed on Dec. 8, 2017.
Claims priority of provisional application 62/432,407, filed on Dec. 9, 2016.
Prior Publication US 2022/0241372 A1, Aug. 4, 2022
Int. Cl. C07K 16/36 (2006.01); A61K 38/17 (2006.01); G01N 33/53 (2006.01)
CPC A61K 38/1709 (2013.01) 20 Claims
 
1. A method for determining an effective dose of a multi-Fc therapeutic comprising:
(a) administering the multi-Fc therapeutic to a subject in need thereof at a starting dose of the multi-Fc therapeutic;
(b) determining blood iC3b level of the subject;
(c) determining that the subject requires a first cumulative escalated dose of the multi-Fc therapeutic if the subject has been determined to have:
(i) a blood iC3b level lower than a predetermined threshold following administration with the starting dose of the multi-Fc therapeutic; or
(ii) a blood iC3b level with a change percent of less than 10%, less than 20%, less than 30%, less than 40%, or less than 50% from baseline; and
(d) administering a first cumulative escalated dose of the multi-Fc therapeutic, wherein the multi-Fc therapeutic comprises multimers of a homodimer and wherein the homodimer comprises a monomer comprising amino acids 21-264 of SEQ ID NO:4.